A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Summary

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  Zilovertamab vedotin

  IV infusion

• Biological
  Rituximab

  IV infusion

• Drug
  Cyclophosphamide

  IV infusion

• Drug
  Doxorubicin

  IV infusion

• Biological
  Rituximab Biosimilar

  IV infusion

• Drug
  Prednisone

  Oral administration or IV infusion

• Drug
  Prednisolone

  Oral administration or IV infusion

Locations (123)